Results 251 to 260 of about 1,312,216 (336)

PML clastosomes prevent nuclear accumulation of mutant ataxin-7 and other polyglutamine proteins [PDF]

, 2006
Alexandre Janer, Elodie Martin, Marie‐Paule Muriel, Morwena Latouche, Hiroto Fujigasaki, Merle Ruberg, Alexis Brice, Yvon Trottier, Annie Sittler   +8 more
openalex   +1 more source

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source

Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma

Matthew M. Weiss, Xiaozhang Zheng, Nan Ji, C. Browne, Veronica T. Campbell, Dapeng Chen, Brad Enerson, Fei Xue, Xin Huang, Christine R. Klaus, Haoran Li, Michele Mayo, Alice McDonald, Atanu Paul, Haojing Rong, Kirti Sharma, Yatao Shi, Anthony Slavin, Dirk Walther, Karen Yuan, Yi Zhang, Xiao Zhu, Joe Kelleher, Duncan Walker, Nello Mainolfi   +24 more
openalex   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Association of vesicular stomatitis virus M protein with host plasma membranes and phenotype of temperature sensitive M protein mutants

, 1988
Douglas S. Lyles, Bruce McCreedy
openalex   +2 more sources

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets [PDF]

, 2018
et al,, Li, Shunqiang, Shao, Jieya
core   +1 more source

Dysregulation of ERAD and Stress Response Proteins by V493F FTO Over-expression: A Proteomic Perspective. [PDF]

In Vivo
Kanli A.
europepmc   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Mutant p53: evolving perspectives. [PDF]

Genes Dev
Efe G, Cunningham K, Rustgi AK, Prives C, Manfredi JJ, Sánchez-Rivera FJ.   +5 more
europepmc   +1 more source